Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACSS2 | Q9NR19 | 2/20 | 0.39 |
| ▸ | PDE3B | Q13370 | 9/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 9/20 | 0.38 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.36 |
| ▸ | PDE2A | O00408 | 9/20 | 0.35 |
| ▸ | P2RY12 | Q9H244 | 7/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | THRA | P10827 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10025466 | 0.91 | FGFR1 (0.39) | PDE3BPDE3AMAPKAPK2KDM4E | |
| SCHEMBL13541777 | 0.86 | PDE3B (0.36) | PDE3BPDE3AMAPKAPK2PDE2AP2RY12 | |
| SCHEMBL10025543 | 0.84 | TLR7 (0.34) | PDE3BPDE3AMAPKAPK2 | |
| SCHEMBL10025535 | 0.82 | KCNA5 (0.35) | PDE3BPDE3AKDM4E | |
| SCHEMBL3497864 | 0.81 | HRH3 (0.44) | PDE3BPDE3A | |
| SCHEMBL6743257 | 0.81 | PPARG (0.32) | PDE3BPDE3AMAPKAPK2KDM4E | |
| SCHEMBL10025541 | 0.81 | ATM (0.39) | PDE3BPDE3AKDM4ETSHR | |
| SCHEMBL10025539 | 0.81 | PPARG (0.33) | PDE3BPDE3AP2RY12KDM4E | |
| SCHEMBL10025536 | 0.78 | HRH3 (0.43) | PDE3BPDE3ATSHR | |
| SCHEMBL10025537 | 0.70 | NPC1 (0.35) | PDE3BPDE3ASLC6A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207173-B2 | Benzimidazoles and analogs thereof as antivirals | ISIS PHARMACEUTICALS, INC. (US) | 2012-06-26 | — | — | US | disclosed |
| US-20100130513-A1 | BENZIMIDAZOLES AND ANALOGS THEREOF AS ANTIVIRALS | ISIS PHARMACEUTICALS, INC. (US) | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130513-A1 | BENZIMIDAZOLES AND ANALOGS THEREOF AS ANTIVIRALS | ZC3HAV1, NXF1, ZC3HAV1L | ACSS2 2477/4885PDE3B 2301/4885PDE3A 2534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.